Abstract
Cardiometabolic syndrome is a mixture of interrelated risk factors predisposing individuals to elevated risk of atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Nuclear receptors, specifically peroxisome proliferator-activated receptors (PPARs), were identified to play a pivotal role in the regulation of metabolic homeostasis. However, with rosiglitazone currently under intense scrutiny great concerns have arisen regarding the safety of the thiazolidinedione PPAR-γ agonist family as a whole. This review discusses the current concern with PPAR-γ agonists by exploring if PPARs can still be considered worth pursuing as a viable target for cardiovascular diseases. We examine current research focusing on identifying ligands that are dual and pan-PPAR agonists, selective PPAR-γ modulators, PPAR-β/δ agonists and that are of natural origin.
Keywords: Cardiometabolic syndrome, diabetes mellitus, herbal and traditional natural medicines, peroxisome proliferator-activated receptor-γ
Current Molecular Pharmacology
Title:Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs)
Volume: 5
Author(s): Tom Hsun-Wei Huang and Basil D. Roufogalis
Affiliation:
Keywords: Cardiometabolic syndrome, diabetes mellitus, herbal and traditional natural medicines, peroxisome proliferator-activated receptor-γ
Abstract: Cardiometabolic syndrome is a mixture of interrelated risk factors predisposing individuals to elevated risk of atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Nuclear receptors, specifically peroxisome proliferator-activated receptors (PPARs), were identified to play a pivotal role in the regulation of metabolic homeostasis. However, with rosiglitazone currently under intense scrutiny great concerns have arisen regarding the safety of the thiazolidinedione PPAR-γ agonist family as a whole. This review discusses the current concern with PPAR-γ agonists by exploring if PPARs can still be considered worth pursuing as a viable target for cardiovascular diseases. We examine current research focusing on identifying ligands that are dual and pan-PPAR agonists, selective PPAR-γ modulators, PPAR-β/δ agonists and that are of natural origin.
Export Options
About this article
Cite this article as:
Hsun-Wei Huang Tom and D. Roufogalis Basil, Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs), Current Molecular Pharmacology 2012; 5 (2) . https://dx.doi.org/10.2174/1874467211205020241
DOI https://dx.doi.org/10.2174/1874467211205020241 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genome Study of Kidney Disease in the Age of Post Genome-Sequencing
Endocrine, Metabolic & Immune Disorders - Drug Targets Diabetes, Cancer and Treatment – A Mini-Review
Current Drug Safety Fetal Protein Restriction, Taurine and Islet Plasticity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Regulation of Insulin Release at Pre-exocytotic Stages of the Secretory Process
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Can Dietary Polyphenols Prevent the Formation of Toxic Compounds from Maillard Reaction?
Current Drug Metabolism Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease
Current Medicinal Chemistry Breast Cancer: Biological Characteristics in Postmenopausal Type 2 Diabetic Women. Identification of Therapeutic Targets
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications
Current Medicinal Chemistry Editorial: Precursors of Cardiovascular Disease in Adolescent Type 1 Diabetes
Current Diabetes Reviews Non-Peptidic Inhibitors of Cysteine Proteases
Mini-Reviews in Medicinal Chemistry Ultrasound Contrast Agents: Updated Data on Safety Profile
Current Pharmaceutical Design Quetiapine to Treat Agitation in Dementia: A Randomized, Double-Blind,Placebo-Controlled Study
Current Alzheimer Research Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability
Current Medicinal Chemistry Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design Impact of Renin-Angiotensin System in Hepatocellular Carcinoma
Current Cancer Drug Targets Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Ezetimibe and Vascular Inflammation
Current Vascular Pharmacology Continuous Glucose Monitoring: Physiological and Technological Challenges
Current Diabetes Reviews Adipose Tissue in the Regulation of Inflammation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)